DBM(C6)-VC-PAB-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).
Structure of 1644228-55-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
DBM(C6)-VC-PAB-MMAE, a potent antibody-drug conjugate (ADC) linker-payload system revolutionizing cancer therapeutics, introduces a groundbreaking approach for targeted treatment.
Targeted Cancer Therapy: Precision-engineered to transport cytotoxic agents directly to cancerous cells while minimizing harm to healthy tissues, DBM(C6)-VC-PAB-MMAE achieves unparalleled accuracy. By linking the payload to antibodies recognizing specific cancer cell surface markers, the payload is unleashed upon internalization, initiating precise cellular destruction with exceptional precision.
Overcoming Drug Resistance: In the realm of cancer treatment, DBM(C6)-VC-PAB-MMAE emerges as a beacon of hope in overcoming resistance encountered in conventional chemotherapy regimens. By exploiting unique biomarkers present on drug-resistant cancer cells, this ADC circumvents resistance mechanisms and efficiently delivers its cytotoxic payload. This strategic maneuver enhances therapeutic effectiveness, particularly in resistant cancer subtypes.
Improved Therapeutic Index: Pioneering cancer therapeutics, ADC technology embodied by DBM(C6)-VC-PAB-MMAE elevates the therapeutic index by offering increased efficacy at lower doses, thereby reducing systemic toxicity. By selectively releasing the cytotoxic agent in the tumor microenvironment, healthy cells are spared, resulting in fewer side effects and enhanced patient outcomes.
Combination Therapy: Embracing a multifaceted strategy in cancer care, DBM(C6)-VC-PAB-MMAE can be combined with complementary modalities, like immune checkpoint inhibitors, to amplify anticancer effects. This synergistic fusion shows potential in reducing tumor size or reshaping the tumor microenvironment to heighten responsiveness to immunotherapy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00019 | Fmoc-VC-PAB-MMAE | 1350456-56-2 | |
BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
BADC-00958 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | |
BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 | |
BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 | |
BADC-01638 | OH-Glu-Val-Cit-PAB-MMAE | 1895916-23-0 | |
BADC-00855 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 | |
BADC-01413 | DBM-MMAE | 1912408-87-7 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.